Chemotherapy for human gastric cancer: A review;Qu'attendre de la chimiothérapie dans le cancer de l'estomac en 2008?

Revue Medicale de Liege

Volumn 63, Issue 9, 2008, Pages 532-541

  Demolin, G ^a   Focan, C ^a,b   Plomteux, O ^a   Kreutz, F ^a   Moeneclaey, N ^a   Focan Henrard, D ^a  

^a Clinique Saint Joseph   (Belgium)

^b CHC Saint Joseph   (Belgium)

Author keywords

Chemotherapy; Review; Stomach cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PEMETREXED; UFT;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG MECHANISM; FEBRILE NEUTROPENIA; HUMAN; NEUTROPENIA; PROGNOSIS; REVIEW; STOMACH CANCER; STOMATITIS; SURGICAL APPROACH; TREATMENT RESPONSE;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 52649110582     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Parkin DM. - Global cancer statistics in the year 2000. Lancet Oncol, 2001, 2, 533-543.
2. Hohenberger P, Gretschel S. - Gastric cancer, Lancet, 2003, 362, 305-315.
3. Pyrhonen S, Kuitunen T, Nyandoto P, et al. - Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer, 1995, 71, 587-591.
4. Murad AM, Santiago FF, Petroianu A, et al. - Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 1993, 72, 37-41
5. Schipper DL, Wagener DJ. - Chemotherapy of gastric cancer. Anticancer Drugs, 1996, 7, 137-149.
6. Glimelius B, Ekstrom K, Hoffman K, et al. - Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 1997, 8, 163-168.
7. Webb A, Cunningham D, Scaffe J, et al. - Randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophageal cancer. J Clin Oncol, 1997, 15, 261-267.
8. Mitry E, Artru P, Taïeb J, et al. - Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5-FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol, 2004, 15, 765-769.
9. Bouche O, Raoul JL, Bonnetain F, et al. - Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5-FU2), LV5-FU2 plus cisplatin or LV5-FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie digestive Group Study - FFCD 9803. J Clin Oncol, 2004, 22, 4319-4328.
10. Ridwelski K, Gebauer T, Fahlke J, et al. - Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol, 2001, 12, 47-51.
11. Roth AD, Ajani J. - Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol, 2003, 14, 1241-1244.
12. Van Cutsem E, Moiseyenko VM, Tjulandin SA, et al. - Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 study group. J Clin Oncol, 2006, 24, 4991-4997.
13. Ajani JA, Moiseyenko VM, Tjulandin SA, et al. - Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatine and fluorouracil in a Phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma : the V-325 study group. J Clin Oncol 2007, 25, 3205-3209.
14. Ajani JA, Moiseyenko VM, Tjulandin SA, et al. - Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma : the V-325 Study group. J Clin Oncol, 2007, 25, 3210-3216.
15. Roth AD, Fazio N, Stupp R, et al. - Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma : a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 2007, 25, 3217-3223.
16. Dank M, Zaluski J, Barone C, et al. - Randomized phase 3 trial of irinotecan (CPT-11) + 5-FU/folinic acid (FA) vs CDDP + FU in 1st-line advanced gastric cancer patients. 2005 ASCO Annual Meeting : Abstract No : 4003.
17. Louvet C, André T, Tigaud JM, et al. - Phase II study of oxaliplatin , 5 fluorouracil and folinic, locally advanced or metastatic gastric cancer patients. J Clin Oncol, 2002, 20, 4543-4548.
18. De Vita F, Orditura M, Matono E, et al. - A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer, 2005, 92, 1644-1649.
19. Lordick F, Lorenzen S, Stollfuss J, et al. - Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer, 2005, 93, 190-194.
20. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. - Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol, 2004, 22, 658-663.
21. Cunningham D, Starling N, Rao S, et al. - Capecitabine and oxaliplatin for advanced esophagogastric cancer. NEJM, 2008, 358, 36-46.
22. Al-Batran S, Hartmann JT, Probst S, et al. - A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin versus fluorouracil, leucovorin and cisplatin. J Clin Oncol, 2006, 24, LBA4016.
23. Boku N. - Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). 2007, ASCO Annual Meeting. Abstract - No. LBA4513.
24. Narahara H. - Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS : S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. 2007, ASCO Annual Meeting. Abstract - No. LBA4514.
25. Bajetta E, Celio L, Buzzoni R, et al. - Efficacy and toxicity of pemetrexed disodium (Alimta) with oral folic acid in patients with advanced gastric cancer. An Oncol, 2003, 14, 15438.
26. Focan C, Kreutz F, Longrée L, et al. - Interest of chronotherapy, in the multidisciplinary management of oesophageal and gastric cancer. Pathol Bio, 2007, 55, 181-185.
27. Waters JS, Norman A, Cunningham D, et al. - Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 1999, 80, 269-272.
28. Vanhoefer U, Rougier P, Wilke H, et al. - Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer : a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 2000, 18, 2648-2657.
29. Ohtsu A, Shimada Y, Shirao K, et al. - Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol, 2003, 21, 54-59.
30. Gunderson LL. - Gastric cancer - patterns of relapse after surgical resection. Semin Radiat Oncol, 2002, 12, 150-161.
31. Wisbeck WM, Becher EM, Russell AH. - Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol, 1986, 7, 13-18.
32. Imanaga H, Nakazato H : Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg, 1977, 2, 213-221,
33. Nakajima T, Fukami A, Ohashi I, et al. - Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm, 1978, 16, 209-216.
34. Nakajima T, Takahashi T, Takagi K, et al. - Comparison of 5-fluorouracil with torafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol, 1984, 2, 1366-1371.
35. Maehara Y, Moraguchi S, Sakaguchi Y, et al. - Adjuvant chemotherapy enhances long term survival of patients with advanced gastric cancer after curative resection. J Surg Oncol, 1990, 45, 169-172.
36. Coombes R, Schein P, Chilvers C, et al. - A randomised trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol, 1990, 8, 1362-1369.
37. Fujii M, Sakabe T, Wakabayashi K, et al. - The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer : A pilot study using 5-FU tablets compared with surgical operation alone. Gan To Kagaku Ryoho, 1994, 21, 1199-1208.
38. Lise M, Nitti D, Marchet A, et al. - Prognostic factors in resectable gastric cancer: Results of EORTC study no. 40813 on FAM adjuvant chemotherapy. Ann Surg Oncol, 1995, 2, 495-501.
39. MacDonald JS, Fleming TR, Petercon R, et al. - Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol, 1995, 2, 488-494.
40. Nakajima T, Nashimoto A, Kitamura M, et al. - Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer : A randomised trial - Gastric Cancer Surgical Study Group. Lancet, 1999, 354, 273-277.
41. Bajetta E, Buzzoni R, Mariani L, et al. - Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol, 2002, 13, 299-307.
42. Nashimoto A, Nakajima T, Furukawa H, et al. - Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer : Japan Clinical Oncology Group 9206-1. J Clin Oncol, 2003, 21, 2282-2287.
43. Hermans J, Bonenkamp Boon M, et al. - Adjuvant therapy after curative resection for gastric cancer : A meta-analysis of randomized trials. J Clin Oncol, 1993, 11, 1441-1447.
44. Earle C, Maroun J. - Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients : Revisiting a meta-analysis of randomised trials. Eur J Cancer, 1999, 35, 1059-1064.
45. Mari E, Floriani I, Tinazzi A, et al. - Efficacy of adjuvant chemotherapy after curative resection for gastric cancer : A meta-analysis of published randomised trials. Ann Oncol, 2000, 11, 837-843.
46. Janunger KG, Hafstrom L, Glimelius B. - Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg, 2002, 168, 597-608.
47. Sakuramoto S, Sasako M, Yamaguchi T, et al. - Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med, 2007, 1, 1810-1820.
48. Macdonald JS, Smaley SR, Benedetti J, et al. - Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345, 725-730.
49. Markman M. - Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract. Surg Gynecol Obstet, 1987, 164, 89-93.
50. Liang H, Wang P, Wang XN, et al. - Prospective randomized trial of prophylaxis of postoperative peritoneal carcinomatosis of advanced gastric cancer : intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. Zhonghua Wai Ke Za Zhi, 2003, 41, 274-277.
51. Mohamed F, Marchettini P, Stuart OA, et al. - Thermal enhancement of new chemotherapeutic agents at mode-rate hyperthermia. Ann Surg Oncol, 2003, 10, 463-468.
52. Crookes P, Leichman C, Leichman L, et al. - Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy. Cancer, 1997, 79, 1767-1775.
53. Fujimoto S, Takahashi M, Mutou T, et al. - Successfull intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 1999, 85, 529-534.
54. Hamazoe R, Maeta M, Kaibara N. - Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer, 1994, 73, 2048-2052.
55. Rosen HR, Jatzko G, Repse S, et al. - Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastric cancer : results of a randomized multicenter trial of the Austrian Working group for Surgical Oncology. J Clin Oncol, 1998, 16, 2733-2788.
56. Yu W, Whang I, Suh I, et al. - Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg, 1998, 228, 347-354.
57. Sugarbaker PH, Yu W, Yonemura Y. - Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy : the evolution of treatment strategies for advanced gastric cancer. Semin Sur Oncol, 2003, 21, 233-248.
58. Yu W, Whang I, Chung HY, et al. - indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer : results of a prospective randomized trial. World J Surg, 2002, 26, 1532.
59. Xu DZ, Zhan YQ, Sun XW, et al. - Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol, 2004, 10, 2727-2730.
60. Yan TD, Black D, Sugarbaker PH. - A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer. J Clin Oncol, 2007, 25, 4614.
61. Wilke H, Preusser P, Fink U, et al. - Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol, 1989, 7, 1318-1326.
62. Plukker J Th, Mulder NH, Sleijfer DTH, et al. - Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg, 1991, 78, 955-958.
63. Rougier P, Mahjoubi M, Lasser P, et al. - Neoadjuvant chemotherapy in locally advanced gastric carcinoma - a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer, 1994, 30, 1269-1275.
64. Yonemura Y, Sawa T, Kinoshita K, et al. - Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg, 1993, 17, 256-261.
65. Cunningham D, Allum WH, Stenning SP, et al. - Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355, 11-20.
66. Ychou M, Pignon JP, Lasser P, et al. - Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE) : FNLCC 94012-FFCD 9703 trial. J Clin Oncol, 2006, 24, 4026.
67. Ajani JA, Winter K, Okawara GS, et al. - Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol, 2006, 24, 3953-3958.
68. Hattori T, Nakajima T, Nakozato H, et al. - Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy. Jpn J Surg, 1990, 20, 127-136.
69. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist, 2004, 9, 282-294.
70. Kopp R, Rothbauer E, Ruge M, et al. - Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results. Cancer Res, 2003, 162, 115-132.
71. Kim JG, Sohn SK, Chae YS, et al. - Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol, 2007, 18, 1030-1036.
72. Pera M, Vidal O, Elizalde J, et al. - Tumor VEGF expression and serum VEGF levels are independent prognostic factors in curatively resected gastric cancer patients. J Clin Oncol, 2006, 24, 4021.
73. Shah MA, Ramanathan RK, Ilson DH, et al. - Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol, 2006, 24, 5201-5206.
74. Pinto C, Di Fabio F, Siena S, et al. - Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol, 2007, 18, 510-517.
75. Lordick F,Lorenzen S, Hegewisch-Becker S, et al. - Cetuximab plus weekly oxaliplatin/5-FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol, 2007, 25, 4526.